Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 78

Sort by

Sort Order Select

Journal Articles

Risk of Infections in Multiple Myeloma in the Era of Novel Agents, a Population-Based Study Based on 8672 Multiple Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry

Cecilie Hveding Blimark, Kristina Carlson, Christopher Day, Sigrun Einarsdottir, Gunnar Juliusson, Moshtak Karma, Dorota Knut-Bojanowska, Gunnar Larfors, Ingemar Turesson, Mariana Villegas Scivetti, Ingigerdur Sverrisdottir

Blood (2023) 142 (Supplement 1): 4696.

https://doi.org/10.1182/blood-2023-174228

Published: 2023

Journal Articles

Income and Education Affect Prognosis and Treatment in Symptomatic Myeloma: A Population-Based Study on 8672 Multiple Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry

Gunnar Larfors, Kristina Elisabet Carlson, Christopher Day, Sigrun Einarsdottir, Gunnar Juliusson, Moshtak Karma, Dorota Knut-Bojanowska, Ingigerdur Sverrisdottir, Ingemar Turesson, Mariana Villegas Scivetti, Cecilie Hveding Blimark

Blood (2023) 142 (Supplement 1): 4723.

https://doi.org/10.1182/blood-2023-180637

Published: 2023

Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2023-188827

Published: 2023

Journal Articles

Vaccine-Preventable Infections in Multiple Myeloma: A Population-Based Study on 8672 Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry

Sigrun Einarsdottir, Ingigerdur Sverrisdottir, Mariana Villegas Scivetti, Christopher Day, Ingemar Turesson, Gunnar Juliusson, Kristina Elisabet Carlson, Gunnar Larfors, Cecilie Hveding Blimark

Blood (2023) 142 (Supplement 1): 4704.

https://doi.org/10.1182/blood-2023-184444

Published: 2023

Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2023) 142 (Supplement 1): 635.

https://doi.org/10.1182/blood-2023-173709

Published: 2023

Journal Articles

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Blood (2023) 142 (Supplement 1): 323.

https://doi.org/10.1182/blood-2023-184703

Published: 2023

Journal Articles

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2023-181709

Published: 2023

Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater

Blood (2023) 142 (5): 446–459.

https://doi.org/10.1182/blood.2023019634

Published: 2023

Includes: Supplemental data

Journal Articles

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Blood (2023) 141 (21): 2657–2661.

https://doi.org/10.1182/blood.2022019160

Published: 2023

Includes: Supplemental data

Journal Articles

Revisiting coexisting chromosomal abnormalities in NPM1 -mutated AML in light of the revised ELN 2022 classification

Linus Angenendt, Christoph Röllig, Pau Montesinos, Farhad Ravandi, Gunnar Juliusson, Christian Récher, Raphaël Itzykson, Zdeněk Ráčil, Andrew H. Wei, Christoph Schliemann

Blood (2023) 141 (4): 433–435.

https://doi.org/10.1182/blood.2022018582

Published: 2023

Journal Articles

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Blood (2022) 140 (Supplement 1): 842–845.

https://doi.org/10.1182/blood-2022-164786

Published: 2022

Journal Articles

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Blood (2022) 140 (Supplement 1): 9125–9127.

https://doi.org/10.1182/blood-2022-157753

Published: 2022

Journal Articles

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Jesse M. Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Thomas Fischer, Bjørn Tore Gjertsen, Patrycja Gradowska, Laimonas Griskevicius, Jeroen J.W.M. Janssen, Gunnar Juliusson, Johan A. Maertens, Markus G Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Peter JM Valk, Bob Lowenberg, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2022) 140 (Supplement 1): 2027–2029.

https://doi.org/10.1182/blood-2022-157009

Published: 2022

Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 71.

https://doi.org/10.1182/blood-2021-146161

Published: 2021

Journal Articles

Costs per Treatment Phase for AML Patients Receiving High-Dose Chemoterapy in Sweden

Emma Hernlund, PhD, Josefine Redig, MSc, Åsa Rangert Derolf, MD PhD, Bjorn Paulsson, MD, Martin Höglund, MD PhD, Simona Vertuani, PhD, Gunnar Juliusson, MD PhD

Blood (2019) 134 (Supplement_1): 2154.

https://doi.org/10.1182/blood-2019-127957

Published: 2019

Journal Articles

Hepatic Leukemia Factor Is Critical for Hematopoietic Stem Cells and Promotes MLL-AF9 Acute Myeloid Leukemia

Aurelie Baudet, PhD, Karolina Paulina Komorowska, PhD, Hultmark Simon, MS, Marcus Järås, PhD, Marion Chapellier, PhD, Gunnar Juliusson, MD PhD, Mattias Magnusson, PhD

Blood (2019) 134 (Supplement_1): 2466.

https://doi.org/10.1182/blood-2019-122661

Published: 2019

Journal Articles

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period

Gunnar Juliusson, Oskar Hagberg, Vladimir Lj Lazarevic, Emma Ölander, Petar Antunovic, Jörg Cammenga, Lovisa Wennström, Lars Möllgård, Mats Brune, Martin Jädersten, Stefan Deneberg, Sören Lehmann, Åsa Rangert Derolf, Martin Höglund

Blood (2019) 134 (18): 1558–1561.

https://doi.org/10.1182/blood.2019001728

Published: 2019

Includes: Supplemental data

Journal Articles

AML Xenografts Undergo Extensive Clonal Competition and Unmask Rare Clones in Patient Samples

Carl Sandén, PhD, Henrik Lilljebjörn, PhD, Christina Orsmark-Pietras, PhD, Karim Saba, MSc, Carl Högberg, PhD, Marianne Rissler, MSc, Vladimir Lazarevic, MD PhD, Gunnar Juliusson, MD PhD, Helena Ågerstam, PhD, Thoas Fioretos, MD PhD

Blood (2018) 132 (Supplement 1): 2621.

https://doi.org/10.1182/blood-2018-99-110497

Published: 2018

Journal Articles

Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow

Vladimir Lazarevic, Christina Orsmark-Pietras, Henrik Lilljebjörn, Louise Pettersson, Marianne Rissler, Anna Lübking, Mats Ehinger, Gunnar Juliusson, Thoas Fioretos

Blood (2018) 131 (5): 577–581.

https://doi.org/10.1182/blood-2017-07-793620

Published: 2018

Includes: Supplemental data

Journal Articles

Monitoring Leukemic Mutations Using Ultrasensitive IBSAFE Digital Droplet Analysis Predicts Relapse of Acute Myeloid Leukemia

Louise Pettersson, MD, Yilun Chen, MSc, Anthony M George, MSc, Christina Orsmark-Pietras, PhD, Henrik Lilljebjörn, MSc, Robert Rigo, MSc, Vladimir Lazarevic, MD PhD, Thoas Fioretos, MD PhD, Gunnar Juliusson, MD PhD, Mats Ehinger, MD PhD, Lao H Saal, MD PhD

Blood (2017) 130 (Supplement 1): 3951.

https://doi.org/10.1182/blood.V130.Suppl_1.3951.3951

Published: 2017

NARROW

Risk of Infections in Multiple Myeloma in the Era of Novel Agents, a Population-Based Study Based on 8672 Multiple Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry

Income and Education Affect Prognosis and Treatment in Symptomatic Myeloma: A Population-Based Study on 8672 Multiple Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Vaccine-Preventable Infections in Multiple Myeloma: A Population-Based Study on 8672 Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Revisiting coexisting chromosomal abnormalities in NPM1 -mutated AML in light of the revised ELN 2022 classification

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Costs per Treatment Phase for AML Patients Receiving High-Dose Chemoterapy in Sweden

Hepatic Leukemia Factor Is Critical for Hematopoietic Stem Cells and Promotes MLL-AF9 Acute Myeloid Leukemia

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period

AML Xenografts Undergo Extensive Clonal Competition and Unmask Rare Clones in Patient Samples

Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow

Monitoring Leukemic Mutations Using Ultrasensitive IBSAFE Digital Droplet Analysis Predicts Relapse of Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only